Overview

This trial is active, not recruiting.

Condition colorectal cancer
Treatments tetwtcea dna (wt cea with tetanus toxoid th epitope), derma vax (electroporation device), gm-csf, cyclophosphamide
Phase phase 1/phase 2
Sponsor Maria Liljefors
Collaborator Karolinska Institutet
Start date December 2009
End date February 2017
Trial size 20 participants
Trial identifier NCT01064375, 2009-009863-75, El-porCEA

Summary

The purpose of this study is to evaluate the safety and immunogenicity of a CEA DNA immunisation approach in patients with colorectal cancer. The DNA plasmid, tetwtCEA, encodes wild type human CEA fused to a tetanus toxoid T helper epitope. The vaccine will be delivered using an intradermal electroporation device, Derma Vax (Cyto Pulse Sciences). The following will be assessed:

- The efficiency of priming immunological responses to CEA by intradermal administration of CEA DNA in combination with electroporation.

- The efficiency of boosting immunological responses to CEA by intradermal administration of CEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA.

- GM-CSF will be administered to half of the subjects primed with CEA DNA in combination with electroporation and any possible adjuvant effects of GM-CSF will be evaluated.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
tetwtcea dna (wt cea with tetanus toxoid th epitope) GM-CSF
Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
derma vax (electroporation device) GM-CSF
Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
cyclophosphamide Sendoxan
One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
(Experimental)
10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
tetwtcea dna (wt cea with tetanus toxoid th epitope) GM-CSF
Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
derma vax (electroporation device) GM-CSF
Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
cyclophosphamide Sendoxan
One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
(Experimental)
5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
tetwtcea dna (wt cea with tetanus toxoid th epitope) GM-CSF
Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
derma vax (electroporation device) GM-CSF
Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
gm-csf GM-CSF
GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
cyclophosphamide Sendoxan
One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA

Primary Outcomes

Measure
To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.
time frame: Within 72 weeks after immunisation

Secondary Outcomes

Measure
To assess the efficiency of boosting immunological responses to CEA by intradermal administration of tetwtCEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA
time frame: Within 72 weeks after immunisation
To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF
time frame: Within 72 weeks after immunsation

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histological confirmed AJCC stage II or III colorectal cancer - Resection of the primary tumour without evidence of remaining macroscopic disease - Allowable standard chemotherapy or radiotherapy in AJCC stage III completed minimum 2 months prior study entry - Patients recruited from vaccination with CEA66 plasmid DNA must have completed trial at 18 months if immune response is proven or proven to be non-immune responders in two consecutive immunoassays. - Age >18 years - Karnofsky performance >80% - Life expectancy of greater than 6 months - Normal organ and marrow function - Normal thyroid function as measured by serum T3, T4 and TSH - Normal echocardiogram regarding arrhythmias (chronic or treated atrial fibrillation allowed) - No concurrent treatment (chemotherapy or biological) may be planned during protocol treatment - Women or men of reproductive potential must agree to use adequate contraception prior to study entry and for up to 3 months after the last injection - Ability to understand and the willingness to sign an informed consent document Exclusion Criteria: - Immunotherapy or systemic corticosteroids within 8 weeks prior to entering the study - Chemotherapy or radiotherapy within 2 months prior to entering the study - Known hypersensitivity to GM-CSF - Previous splenectomy or radiation therapy of the spleen - Pregnancy or nursing - HIV seropositivity - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic intracranial disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - History of severe neurological, cardiovascular, renal, hepatic, respiratory, bone marrow dysfunction, organ graft or autoimmune disease (treated or not) - Concomitant medication with an anticoagulant (acetylsalicylic acid and low-molecular weight heparin in prophylactic dose allowed) - Other malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years - Cardiac demand pacemakers or surgically implanted defibrillators. - Patients that has any metal implants in the area of the injection, (e.g. shoulder implant in the upper arm or shoulder girdle)

Additional Information

Official title Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer
Principal investigator Maria Liljefors, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Karolinska University Hospital.